DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / LSP Or Life Sciences Partners
LSP Or Life Sciences Partners
Institutional venture firm · probableAmsterdamlspvc.comSEC exempt reporting adviserone firm, 3 filing advisers
This firm files as 3 advisers on lspvc.com: EQT Fund Management S.A.R.L, LSP Advisory Bv. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
venture manager, reported GAV $76M across 6 vehicles
Importance
45
elevated
Active deployment
30
moderate
Emerging
0
low
Completeness
81
high
Freshness
100
high
Research priority
12
low
Identity and regulatory footprint
- Headquarters
- Amsterdam, Netherlandsadviserinfo.sec.gov
- Office address
- JOHANNES VERMEERPLEIN 9, Amsterdam, 1071 DVadviserinfo.sec.gov
- Business phone
- +31 20 664 5500adviserinfo.sec.gov
- Website
- HTTP://WWW.LSPVC.COM
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Mar 22, 2023
- Private funds reported
- 9 (9 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $720Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- EQT Treasury Ab (Sole Shareholder), E; EQT Life Sciences Group Bv (Sole Shareholder), E; EQT Ab (Sole Shareholder), E
- business phone
- +31 20 664 5500adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
13 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech, medtech, climate
- Stages
- series b, growth, early, multi stage
- Geography
- europe, france, globally, japan, united states
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series b 50%series c 50%
Stage at first entry
series b 50%series c 50%
Sectors
unknown 92%Other 8%
lead rate 33%follow-on rate 0%new logos, 12 months 13
Funds and vehicles
6 reported, 3 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Life Sciences Partners IV Bv | Fund | unknown | Unknown | $27.8M Mar 22, 2023 | 5 | unknown | unknown |
| Life Sciences Partners IV Cv | Fund | unknown | Unknown | $25.1M Mar 22, 2023 | 17 | unknown | unknown |
| Life Sciences Partners III Bv | Fund | unknown | Unknown | $11.1M Mar 22, 2023 | 16 | unknown | unknown |
| Life Sciences Partners III Cv | Fund | unknown | Unknown | $5.8M Mar 22, 2023 | 11 | unknown | unknown |
| Life Sciences Partners III Co-Investment Bv | SPV or co-invest vehicle | unknown | Unknown | $5.7M Mar 22, 2023 | 2 | unknown | unknown |
| Life Sciences Partners II Bv | Fund | unknown | Unknown | $114,928 Mar 22, 2023 | 8 | unknown | unknown |
| LSP Health Economics Fund B Cv | Fund | 2015 adv first reported | Wound down | $10.7M Mar 29, 2017 | 2 | unknown | unknown |
| LSP Health Economics Fund Cv | Fund | unknown | Wound down | $94.8M Mar 29, 2017 | 10 | unknown | unknown |
| LSP Bioventures Cv | Fund | unknown | Wound down | $0 Mar 29, 2017 | 2 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
14 current, 0 departed
Bert Janssens
PartnerPartner, Co-Head of Private Capital
Henry Steinberg
PartnerPartner, Global Head of EQT Real Estate
James Yu
PartnerPartner, Head of Global Client Solutions
Jeremy Coller
PartnerHead and Chief Investment Officer of Coller EQT
Joachem Guenter Rothe
PartnerManaging Director · since Feb 1, 2002
Marcus Antonius Wegter
PartnerManaging Director · since Mar 1, 2008
Martijn (nmn) Kleijwegt
PartnerManaging Director · since Feb 1, 1999
Masoud Homayoun
PartnerPartner, Head of EQT Infrastructure
Rene Robert Kuijten
PartnerManaging Director · since Feb 1, 2001
Alexandra Edlund
Platform and operationsChief People Officer
Bastiaan (nmn) Vaessen
Platform and operationsLegal Counsel · since Feb 1, 2008
Christina Drews
Platform and operationsChief Operating Officer
Gustav Segerberg
Platform and operationsChief Financial Officer
Merijn (nmn) Klaassen
Platform and operationsChief Financial Officer · since Mar 1, 2008
Investments on record
13 edges, 13 companies, 1 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
39 relationships from shared deals, counted for the whole firm
Tiger Global 2 shared · recurring · they led 1 · we led 1Omega Fund Management, LLC 2 shared · recurringPivotal 1 shared · one timeCRV, LLC 1 shared · one timeAlibaba 1 shared · one timeFuel Capital 1 shared · one timeShasta Ventures 1 shared · one timeCivilization Ventures Management, LLC 1 shared · one timeMadrona Venture Group, LLC 1 shared · one timeSapphire Ventures, LLC 1 shared · one timeDatadog 1 shared · one timeIconiq Capital, LLC 1 shared · one timeSalesforce Ventures 1 shared · one timeNSV Management LLC 1 shared · one timeMaterial 1 shared · one timeFrazier Healthcare Partners 1 shared · one timeBand of Angels Acorn Fund, LLC 1 shared · one timeVirtue Ventures Management L.L.C. 1 shared · one timeTwelve Below 1 shared · one timeDarwin Ventures, LLC 1 shared · one time · we led 1LYFE Capital 1 shared · one time · they led 1Revelation Partners 1 shared · one time · they led 1Swisscom Ventures 1 shared · one time · we led 1Crosslink Capital, Inc. 1 shared · one time · we led 1Bessemer Venture Partners 1 shared · one time · they led 1 · we led 1Softbank, Inc. 1 shared · one time · they led 1 · we led 1Bain Capital Life Sciences 1 shared · one time · they led 1 · we led 1PayPal Ventures 1 shared · one time · we led 1PTV Healthcare Capital 1 shared · one time · they led 1 · we led 1Life Sciences 1 shared · one time · they led 1Life Sciences 1 shared · one time · they led 1Omega Funds 1 shared · one timeKalehua Capital 1 shared · one timePerceptive Advisors 1 shared · one timeOmega Funds 1 shared · one timeFountain Healthcare Partners 1 shared · one timeEnterprise Ireland 1 shared · one timeAtlantic Bridge 1 shared · one timeMVM Partners LLP 1 shared · one time · they led 1
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
16 dated events
- Mar 30, 2021LSP Dementia Fund first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $5,491,005Fund first reported on Form ADVFundsFactLSP Dementia FundSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2018Life Sciences Partners 6 Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund)Fund first reported on Form ADVFundsFactLife Sciences Partners 6 CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2018LSP Bioventures Cv no longer reported on Form ADV by LSP Or Life Sciences PartnersFund no longer reportedFundsInferenceLSP Bioventures CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2018LSP Health Economics Fund B Cv no longer reported on Form ADV by LSP Or Life Sciences PartnersFund no longer reportedFundsInferenceLSP Health Economics Fund B CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2018LSP Health Economics Fund Cv no longer reported on Form ADV by LSP Or Life Sciences PartnersFund no longer reportedFundsInferenceLSP Health Economics Fund CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2015LSP Health Economics Fund B Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $10,490,183Fund first reported on Form ADVFundsFactLSP Health Economics Fund B CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2015Life Sciences Partners V Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $96,848,226Fund first reported on Form ADVFundsFactLife Sciences Partners V CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012LSP Bioventures Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $55,182,303Fund first reported on Form ADVFundsFactLSP Bioventures CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012LSP Or Life Sciences Partners first filed Form ADV (ERA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012LSP Health Economics Fund Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $64,750,065Fund first reported on Form ADVFundsFactLSP Health Economics Fund CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners II Bv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $45,849,343Fund first reported on Form ADVFundsFactLife Sciences Partners II BvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners III Bv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $54,170,370Fund first reported on Form ADVFundsFactLife Sciences Partners III BvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners III Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $28,696,954Fund first reported on Form ADVFundsFactLife Sciences Partners III CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners III Co-Investment Bv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $23,771,498Fund first reported on Form ADVFundsFactLife Sciences Partners III Co-Investment BvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners IV Bv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $56,609,904Fund first reported on Form ADVFundsFactLife Sciences Partners IV BvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012Life Sciences Partners IV Cv first reported on Form ADV by LSP Or Life Sciences Partners (Venture Capital Fund), GAV $51,424,264Fund first reported on Form ADVFundsFactLife Sciences Partners IV CvSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $76M across 6 vehicles
Evidence
39 observations from 2 sources